Comparison of the clinical effect of dutasteride therapy for benign prostatic hyperplasia when initiated at different time points: A multicentre, observational, retrospective chart review study-Reference-Cited by-同舟云学术

Comparison of the clinical effect of dutasteride therapy for benign prostatic hyperplasia when initiated at different time points: A multicentre, observational, retrospective chart review study

Published:2019-10-11 Issue:12 Volume:73 Page:
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Shima Yukiko¹,Kawano Yoshiaki¹,Kobayashi Akihiro²,Yamanishi Tomonori³,Takeda Hirokazu⁴,Palacios‐Moreno Juan Manuel⁵^ORCID,Yamada Masahiro¹^ORCID,Masumori Naoya⁶,Fukuta F,Nanri M,Nishino Y,Sagiyama K,Tsujimoto Y,Arai Y,Ohoka H,Yamaguchi T,Nagao K,Noma Y,Suzuki K,Okamoto T,Enomoto Y,Sakuma T,Sakai I,Nagae H,Torii S,Hiura M,Matsushita M,Nozawa E,Kurokawa S,Mitsui Y,Miyakoda K,Kato S,Yoshikawa K,Kuwahara Y,Sakai H,Hagiwara N,Kasuya Y,Miyamae K

Affiliation:

1. Development and Medical Affairs GlaxoSmithKline Tokyo Japan

2. Biomedical Data Sciences GlaxoSmithKline Tokyo Japan

3. Department of Urology Continence Center Dokkyo Medical University Tochigi Japan

4. Tosei General Hospital Aichi Japan

5. Research and Development Chief Medical Office GlaxoSmithKline Madrid Spain

6. Department of Urologic Surgery and Andrology Sapporo Medical University School of Medicine Sapporo Japan

Funder

GlaxoSmithKline

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.13418

Reference21 articles.

1. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

2. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey

3. The management of lower urinary tract symptoms in men

4. Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education ( PROBE ) II survey

5. American Urological Association.Management of Benign Prostatic Hyperplasia (BPH).2010[cited 2019 1st February];https://www.auanet.org/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cutoff value of transitional zone index predicting the efficacy of dutasteride on subjective symptoms in patients with benign prostate hyperplasia;LUTS: Lower Urinary Tract Symptoms;2022-02-16

2. Postoperative medical treatment of lower urinary tract symptoms after benign prostatic hyperplasia surgery. Are we underestimating the problem?;Current Opinion in Urology;2021-06-25

3. Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or severe symptoms;British Journal of Clinical Pharmacology;2021-01-19

4. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression;World Journal of Urology;2020-12-18